Physician profile
William Eugene Cannady
NPI 1770763021
$949.59
in general payments reported to CMS, 2019-2025
18 companies · $86.55 in 2025
The $86.55 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.06 · 2020: $115 · 2021: $203 · 2022: $134 · 2023: $179 · 2024: $136 · 2025: $86.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $277.04 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $204.59 | 2021-2022 | |
| Pfizer INC. | $79.91 | 2019-2021 | |
| Glaxosmithkline, LLC. | $60.27 | 2022-2025 | Pediarix, Bexsero, Menveo |
| Adlon Therapeutics L.P. | $44.18 | 2020-2021 | |
| Kaleo, INC. | $39.53 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $34.84 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.56 | 2019-2022 | |
| Sobi, INC | $28.13 | 2022-2023 | |
| Seqirus USA INC | $25.27 | 2025 | Flucelvax |
| Novo Nordisk INC | $18.60 | 2023 | Wegovy |
| Genentech USA, INC. | $17.92 | 2020 | |
| Neos Therapeutics, LP | $16.69 | 2019 | |
| Tris Pharma INC | $15.16 | 2022 | |
| Cranial Technologies, INC | $15.09 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.36 | 2025 | Gardasil 9 |
| Biogen, INC. | $13.95 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cannady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.